Kowa Chemical

Kowa Company, Ltd. is a diversified Japanese multinational conglomerate with a significant focus on the pharmaceutical and healthcare industries. Founded in 1894, the company's pharmaceutical division specializes in the research, development, and commercialization of therapies for cardiovascular, metabolic, and ophthalmological conditions. Kowa is best known for its development of the blockbuster statin Livalo (pitavastatin) and the selective PPAR-alpha modulator Parmodia (pemafibrate). The company also maintains a robust presence in the chemical trading and manufacturing sectors, producing a wide range of industrial and specialty chemicals. With a global reach, Kowa operates research facilities and commercial subsidiaries across Asia, Europe, and North America.